Photocure fundamentale forhold (PHO)

TekBot · januar 26, 2021, 7:38am

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

Agreement Expands Photocure’s Hexvix[®]/Cysview[®] Franchise Footprint to over
30 Countries

…

Vis børsmeldingen

Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer
Company focused on delivering transformative solutions to improve the lives of
bladder cancer patients, announces that it has entered into a partnership
agreement with Asieris MediTech Co., Ltd. (Asieris), a division of Jiangsu
Yahong Meditech Co., Ltd., whereby Asieris has obtained exclusive rights to
register and commercialize Hexvix[®] in Mainland China and Taiwan.

Based on the Agreement, Photocure will receive an upfront payment of USD 750,000
from Asieris for the rights to Hexvix in the designated territories, as well as
payments of up to USD 1.4 million for the achievement of certain regulatory
milestones including market approvals in Mainland China and Taiwan. The Company
will manufacture and supply Hexvix, and receive a transfer price from Asieris
representing a markup on product provided under the Agreement. Photocure will
also receive royalties on product sales.

“Expanding our business geographically is a strategic priority at Photocure, and
we are very pleased to partner with Asieris to commercialize Hexvix in both
Mainland China and Taiwan,” said Dan Schneider, President and CEO of Photocure.
“This marks our second strategic agreement with Asieris, a well-run and well
-capitalized company that is executing ahead of plan on the clinical development
of Cevira[®,] which we licensed to them in July 2019. Asieris solely focuses on
the development and commercialization of innovative products in the field of
genitourinary diseases, and we look forward to collaborating with them to bring
the important benefits of Hexvix to patients suffering from bladder cancer in
Mainland China and Taiwan.”

Asieris will fund all costs to secure regulatory approvals of Hexvix in Mainland
China and Taiwan, and expects to begin the regulatory processes immediately.
Given the current market approvals of Hexvix/Cysview in both the U.S. and Europe
based on well-documented evidence of safety and efficacy, Asieris plans to
explore regulatory pathways for expedited approvals in Mainland China and
Taiwan. During the regulatory review and approval process for Hexvix, Asieris
plans to initiate launch preparations including reimbursement applications and
collaborations with blue light cystoscopy (BLC[®]) equipment providers. Asieris
is responsible for all costs related to commercialization of Hexvix in the
designated territories. Photocure will provide regulatory dossier information to
support the application and regulatory review process, and will also provide
training to Asieris’ employees, global promotional materials, and commercial
support.

“Photocure is a global leader in bladder cancer management, and we are very
excited to add a second product from Photocure to our pipeline. We want to make
this breakthrough technology available to physicians and patients in China as
soon as possible.” said Kevin Pan Ph.D., Founder and CEO of Asieris. “Hexvix
adds a great deal of synergy to Asieris’ strategic focus on genitourinary
cancers and other diseases. Together with our drug candidates for NMIBC
treatment in the clinical development, Asieris is building up a combination of
potentially the most advanced technologies in order to provide the best care for
NMIBC patients in China.”

According to GloboCan, the reported incidence of bladder cancer in Mainland
China is approximately 85 000 new patients annually, which is slightly higher
than that in the U.S., but with a healthcare system that is still developing.
There are significant differences in incidence rates between urban and rural
areas, with access to specialty care mainly available in urban areas. The burden
of bladder cancer in Mainland China is expected to increase in the next few
years according to a study published in Cancer Management and
Research (https://doi.org/10.2147/CMAR.S189220).

Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the sixth most common cancer worldwide with 1 650 000
prevalent cases (5-year prevalence rate), 550 000 new cases and almost 200 000
deaths annually in 2018.[1]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. Incidence/mortality by
population. Available at: http://globocan.iarc.fr/Pages/bar_pop_sel.aspx
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html

About Asieris
Asieris strives to become a leading pharmaceutical company focusing on
genitourinary tumors and related diseases. Asieris adheres to a growth strategy
driven by in-house research and development, supplemented by in-licensing, to
rapidly establish a leadership position in the field of focus. Asieris currently
has multiple products under late-stage clinical development and owns proprietary
platforms for the discovery of new antitumor and antimicrobial drugs. Asieris
has offices and operations in Shanghai, Beijing, and Taizhou City of Jiangsu
Province in Mainland China, Philadelphia in the US, and London in UK. For more
information, please visit www.asieris.com.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix[®]/Cysview[®] is a drug that preferentially accumulates in cancer cells
in the bladder making them glow bright pink during Blue Light Cystoscopy
(BLC[®]). BLC with Hexvix/Cysview[ ]improves the detection of tumors and leads
to more complete resection, fewer residual tumors and better management
decisions.

Cysview[® ]is the tradename in the U.S. and Canada, Hexvix[® ]is the tradename
in all other markets. Photocure is commercializing Cysview/Hexvix directly in
the U.S. and Europe, and has strategic partnerships for the commercialization of
Hexvix/Cysview in Canada, Chile, China, Australia and New Zealand. Please refer
to https://photocure.com/partnering-with-photocure/our-partners/ for further
information on our commercial partners.

For further information, please contact:

Photocure

Dan Schneider
President and CEO
Tel: +1-609 759-6515
Email: ds@photocure.com

Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

Savepig · januar 26, 2021, 12:50pm

26.1.2021, 13:28 · TDN Finans Delayed

PHO(NY): ASIERIS-AVTALE REN OPPSIDE, PRIS I KINA USIKKERHETSMOMENT -ANALYTIKER

(Rettet selskapsnavn i overskrift og ingress)

Oslo (TDN Direkt): DNB-analytiker Patrik Ling mener Photcures Hexvix-avtale med Asieris er ren oppside for Photocure, men trekker frem prisen på produktet i Kina som et usikkerhetsmoment. Photocure sier avtalen er i henhold til hva man kan forvente.

Asieris har fått eksklusive rettigheter til å registrere og kommersialisere blærekreftbehandlingen Hexvix i fastlands-Kina og Taiwan.

Analytiker Patrik Ling i DNB Markets er positiv til samarbeidet med Asieris. Han trekker frem at Photocure får produktet ut i nye markeder der selskapet ikke er aktive i dag, samtidig som det er partneren i Kina og Taiwan som tar kostnaden for jobben.

I mitt perspektiv, og det er dette børsen også ser, så er dette ren oppside, sier han til TDN Direkt tirsdag.

Photocure får en forhåndsbetaling på 750.000 dollar og regulatoriske milepæler på totale 1,4 millioner dollar. Det betales ingen milepeler utover det, men Photocure vil motta royalties på produktsalg.

Man vet allikevel ikke hva Photocure vil ende opp med i kroner og øre til slutt. Ling sier Photocure vil få en bedre royalty-avtale fra salget sammenlignet med den de har med Ipsen i Europa, men han påpeker at prisene i Kina er lavere.

Om prisnivået på testene ligger på drøyt 1.000 dollar i USA, og 400 euro i Europa, så kommer prisene i Kina til å ligge på maks 200 euro. Det er en royalty på mye lavere priser, men ettersom Photocure ikke har noen direkte kostnader fra dette her, så er det en positiv butikk for dem uansett, sier Ling.

Og prisnivået er et usikkerhetsmoment i avtalen, påpeker analytikeren.

Det vi ikke vet noe om er prisnivået på en slik test. Jeg kan jo gjette meg frem til en rimelig royalty, men jeg vet ikke hva jeg skal beregne royaltyen på, sier han.

Finansdirektør Erik Dahl i Photocure kan ikke si noe om prisnivået på testene i avtalen.

Jeg tør ikke gjette på hva det vil koste å gjøre en test i Kina, spesielt fordi vi ikke vet omfanget myndighetene måtte ønske, sier han til TDN Direkt tirsdag.

Når det gjelder royalty-grunnlag ønsker Photocure av hensyn til Asieris ikke å gå ut med dette. Andre farmasiselskaper som opererer i Kina, opplever imidlertid et lavere prisnivå der enn i for eksempel Europa, bekrefter Dahl.

Dahl vil heller ikke si noe om hva Photocure har antatt i royalties fra avtalen.

Avtalen er inkluderer det man vanligvis skal forvente av en avtale av denne arten, sier han.

Et annet usikkerhetsmoment er at det trengs et blålyscystoskop som tillegg ved bruk av Hexvix i behandlingen av blærekreft.

En klinikk kan ikke bruke dette med en gang. De må først kjøpe utstyr, så det er en komplisert salgsprosess, sier Ling i DNB Markets.

For at salget av Hexvix skal starte i Kina og Taiwan trengs det regulatoriske godkjenninger. Kinesiske myndigheter krever i visse tilfeller kliniske studier på kinesiske pasienter og andre ganger ikke.

Dersom Asieris starter med registrering umiddelbart vil produktet i beste fall være godkjent i slutten av 2022. Dersom det det trengs en klinisk studie må man legge på ett år og da er vi i slutten av 2023, sier Ling.

Arbeidet med å få Hexvix godkjent vil starte umiddelbart, ifølge finansdirektør Dahl i Photocure.

Tekspert · februar 1, 2021, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (330 likes)

@Snoeffelen (157 likes)

@Savepig (157 likes)

Resten av topp 10:

@myk (56 likes)
@Sponplate (28 likes)
@togulle (27 likes)
@tooeasy891 (27 likes)
@solskimm (25 likes)
@Fornybar (23 likes)
@rosk82 (19 likes)

Gratulerer!

Savepig · februar 11, 2021, 12:34pm

Photocure market cap dundrer i vei, snart over 3 milliarder

TekBot · februar 24, 2021, 7:59am

Photocure ASA: Invitation to presentation of fourth quarter and preliminary full year 2020 financial results

Oslo, Norway, 24 February 2021: Photocure ASA (Photocure, PHO: OSE) will
announce the fourth quarter and preliminary full year 2020 financial results on
Wednesday 3 March 2021 at 07:00 CET and invites investors, analysts and the
…

Vis børsmeldingen

media to a presentation at 14:00 CET the same day.

The investor presentation will be streamed live and be hosted by Daniel
Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and
questions can be submitted throughout the event.
The quarterly report and presentation will be published at 07:00 CET and will be
publicly available at www.photocure.com. The streaming event is available
through https://channel.royalcast.com/landingpage/hegnarmedia/20210303_1/

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway) Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Tekspert · mars 1, 2021, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (346 likes)

@Snoeffelen (190 likes)

[quote=“Snoeffelen, post:3801, topic:18877”]

@Savepig (119 likes)

Resten av topp 10:

@tooeasy891 (56 likes)
@togulle (43 likes)
@solskimm (42 likes)
@myk (36 likes)
@Sponplate (28 likes)
@Fornybar (25 likes)
@Quadruple (15 likes)

Gratulerer!

TekBot · mars 3, 2021, 6:00am

Photocure ASA: Results for the fourth quarter of 2020

Oslo, Norway, 3 March 2021: Photocure ASA (OSE:PHO) reports Hexvix[®]/Cysview[®]
revenues of NOK 97.7 million in the fourth quarter of 2020 (Q4 2019: NOK 58.8).
Product revenues increased 20% in FY2020 representing strong execution in an
…

Vis børsmeldingen

unprecedented year. Due to the ongoing pandemic, the Company suspends guidance
for its 2023 revenue ambition in the range of NOK 1 billion. Photocure plans to
re-issue financial guidance once the impact from Covid-19 is significantly
diminished and physician practices and patient flow have normalized in both the
U.S. and Europe.

“Photocure grew sales in 2020 despite the significant operational challenges
during a major global pandemic,” says Dan Schneider, President & Chief Executive
Officer of Photocure. “Despite the limited access to hospitals and physicians
due to Covid-19, we still achieved positive growth in the U.S. Key
accomplishments for the year included: continuing to generate growth in Cysview
product sales and installations of BLC equipment in the U.S.; successfully
integrating the European Hexvix business and launching commercial operations on
1 October; generating value with our partner, Asieris, who is advancing Cevira
through Phase III development, and working with our licensing partners to expand
Hexvix use worldwide.”

Photocure reported total group revenues of NOK 97.9 million in the fourth
quarter of 2020 (NOK 115.6 million) with an EBITDA before restructuring of NOK
15.2 million (NOK 54.8 million), and where the corresponding period in 2019
included sign-on fee and milestone payments of NOK 56.5 million. Hexvix/Cysview
revenues were NOK 97.7 million (NOK 58.8 million). Growth in the U.S. market
continued, despite limited access to hospitals and physicians due to the Covid
-19 pandemic, with in-market unit sales up 11%, while European revenues grew
83.8% following a successful launch of the Company’s commercial organization in
markets previously operated by Ipsen Pharma SAS.

The installed base of cystoscopes in the U.S. was 268 at the end of the fourth
quarter, an increase of 45 units or 20% since the end of 2019. Blue Light
Cystoscopy (BLC[®]) in the surveillance setting is a key priority for Photocure
in the U.S. market. By the end of the fourth quarter, a total base of 38
flexible cystoscopes have been installed representing a 46% increase over the
prior year, giving more patients access to blue light cystoscopy procedures with
less constraints in the office-based setting.

“I am pleased with how we managed through these unprecedented times and proud of
our employees for adapting to changing working conditions and continuing to
serve our patients and customers. Our performance in dealing with the business
volatility throughout 2020, including the rebound in the third quarter, gives me
confidence in the periods ahead,” Schneider adds.

The ongoing Covid-19 pandemic adds continued uncertainty to Photocure’s near
-term business forecast, which impacts the reliability of financial estimates.
However, the Company believes that the benefits of blue light cystoscopy with
Hexvix/Cysview offering superior detection and management of bladder cancer will
continue to be adopted and become the standard of care. Procedures are expected
to rebound back to pre-Covid-19 growth rates in the U.S. in places where bladder
cancer patient care has been disrupted by Covid-19. In the newly acquired
European markets, the Company also expects to see significant growth
opportunities.

“Given the ongoing pandemic conditions, we have suspended our guidance for 2023
revenues in the range of NOK 1 billion. However, we plan to re-issue financial
guidance once the impact of Covid-19 is significantly diminished and physician
practices and patient flow have normalized in both the U.S. and Europe.
Importantly, we are continuing to execute on our business plan to become a
leader in the bladder cancer treatment segment, and we remain well-prepared to
return to our prior growth trajectory when the pandemic is resolved,” Schneider
concludes.

Please find the full financial report and presentation enclosed.

EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
fourth quarter 2020 financial report on pages 26-27.

Photocure will present its fourth quarter 2020 report on Wednesday 3 March 2021
at 14:00 CET. The investor presentation will be streamed live and be hosted by
Dan Schneider, CEO and Erik Dahl, CFO.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20210303_1. The
presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

David Moskowitz
Head of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media Enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mars 25, 2021, 10:27am

Photocure ASA - Initiation of a share buyback

Oslo, Norway, 25 March 2021: Photocure ASA (“Photocure” or the “Company”) has
decided to initiate a buyback of up to 72,500 of its own shares for a total
maximum amount of NOK 10,875,000. The buyback program may be carried out in the
…

Vis børsmeldingen

period from this announcement and until 22 April 2021.

The purpose of the program is to acquire shares that can be used as settlement
in the Company’s share-based incentive scheme. Any acquired shares may also be
used for subsequent reduction of the capital of the Company or to meet
obligations arising from debt financial instruments that are exchangeable into
equity instruments in compliance with the EU Market Abuse Regulation article 5,
and as approved by the general meeting of the Company.

The buybacks will be made in accordance with the authorisation granted to the
board of directors by the Company’s annual general meeting held on 10 June 2020.
According to the authorisation, up to 2,397,603 may be purchased at a minimum of
NOK 0.50 and a maximum of NOK 150 per share. The authorisation is valid until
the annual general meeting on 20 May 2021.

All acquisitions under the buyback program will be executed on Euronext Oslo
Børs. The execution of any repurchases will depend on market conditions, the
buyback programme may be discontinued at any time and the Company may resolve to
terminate the buyback programme before the threshold set out above is reached.

Photocure owns 15,666 own shares in the Company as of the date of this
announcement.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This is information is made public by the Company pursuant to the EU Market
Abuse Regulation article 5, as supplemented by Commission Delegated Regulation
(EU) 2016/1052, and is subject to the disclosure requirements pursuant to
Section 5-12 the Norwegian Securities Trading Act.

Kilde

TekBot · mars 25, 2021, 10:37am

Photocure ASA: Exercise of employee share options and share capital increase

Oslo, Norway, 25 March 2021: Participants in Photocure ASA’s (“Photocure” or the
“Company”) share option program have on 25 March 2021 exercised a total of
102,533 options distributed as follows:
…

Vis børsmeldingen

· 6,533 options exercised according to the option program for 2017 at a strike
price of NOK 38.06;
· 73,500 options exercised according to the option program for 2019 at a
strike price of NOK 50.72; and
· 22,500 sign-on options exercised at a strike price of NOK 56.83.

Each option gives a right to receive one share in the Company. The share options
are described in note 7 and 20 in Photocure’s annual financial statements for
2019.

Following the exercise, the Board of Directors, pursuant to authorisation
granted by the Company’s Annual General Meeting, has decided to increase the
Company’s share capital by NOK 51,266.50 by issuing 102,533 new shares, of par
value NOK 0.50. Subsequent to the transaction, Photocure’s share capital will be
NOK 13,410,034.50 divided into 26,820,069 shares, each share having a par value
of NOK 0.50 and carrying one vote in the Company’s general meeting.

The following options are exercised by primary insiders:

· Dan Schneider, CEO, has exercised 50,000 options.
· Erik Dahl, CFO, has exercised 10,000 options.
· Geoffrey Coy, VP and General Manager of U.S. Operations, has exercised
22,500 options.
· Grete Hogstad, VP Global Strategic Marketing & Business Development, has
exercised 6,250 options.
· Kari Myren, VP Global Medical Affairs and Clinical Development, has
exercised 6,250 options.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

The primary insiders mentioned above have transferred their rights to receive
shares resulting from the exercise of options to a third party. Following a sale
of shares, the primary insiders will receive the net proceeds after deduction of
the strike price and accrued tax. The primary insiders will use the full net
proceeds to purchase shares in Photocure. The sales amount and the number of
shares purchased will be finally determined on the basis of the price
subsequently obtained by the third party in the market. The results of the sales
process will be announced in a separate stock exchange notice when known.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

TekBot · mars 26, 2021, 6:55am

Photocure ASA: Acquisition of own shares under the share buy-back program for incentive scheme

Oslo, Norway, 26 March 2020: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 25 March 2021
regarding initiation of a share buyback program.
…

Vis børsmeldingen

The Company has completed its share buyback program. The Company has acquired a
total of 33 041 own shares at a price per share of NOK 130.6672. A report of all
the transactions relating to the buy-back programme, in a detailed form and in
an aggregated form is attached.

The shares acquired is used for the Company’s incentive scheme and sold to
employees.

After the acquisition and sale to employees, Photocure owns 15,666 own shares in
the Company.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This is information is made public by the Company pursuant to the EU Market
Abuse Regulation article 5, as supplemented by Commission Delegated Regulation
(EU) 2016/1052, and is subject to the disclosure requirements pursuant to
Section 5-12 the Norwegian Securities Trading Act.

Kilde

TekBot · mars 26, 2021, 7:45am

Photocure ASA: Exercise of employee share options

Oslo, Norway, 26 March 2021: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 25 March 2021
regarding exercise of share options.
…

Vis børsmeldingen

The price for option shares sold by primary insiders have been determined at a
price of NOK 130.6672 per share.

The primary insiders having exercised options have used the net proceeds from
the sale of option shares to purchase shares in Photocure at a price per share
of NOK 130.6672 as follows:

· Dan Schneider, CEO, has purchased 17,980 shares.
· Erik Dahl, CFO, has purchased 3,236 shares.
· Geoffrey Coy, VP and General Manager of U.S. Operations, has purchased 8,081
shares.
· Grete Hogstad, VP Global Strategic Marketing & Business Development, has
purchased 1,872 shares.
· Kari Myren, VP Global Medical Affairs and Clinical Development, has
purchased 1,872 shares.

The shares are purchased at the stated price from Photocure’s holding of own
shares. Following the transaction Photocure will hold 15,666 own shares.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

TekBot · mars 29, 2021, 9:11am

Photocure ASA: Share capital increase registered

Oslo, Norway, 29 March 2021: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 25 March 2021
regarding a share capital increase following the exercise of share options.
…

Vis børsmeldingen

The issuance of 102,533 new shares has been registered with the Norwegian
Register of Business Enterprises. Following registration, the share capital of
Photocure is NOK 13,410,034.50 divided into 26,820,069 shares, each share having
a par value of NOK 0.50 and carrying one vote in the Company’s general meeting.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to sections
5-12 of the Norwegian Securities Trading Act.

Kilde

Tekspert · april 1, 2021, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (401 likes)

@Snoeffelen (126 likes)

[quote=“Snoeffelen, post:3801, topic:18877”]

@Savepig (117 likes)

Resten av topp 10:

@togulle (59 likes)
@tooeasy891 (56 likes)
@rosk82 (52 likes)
@solskimm (44 likes)
@Fornybar (41 likes)
@Boykie (28 likes)
@roblar (23 likes)

Gratulerer!

Savepig · april 2, 2021, 2:27pm

Pho topp 50 % er nå

60,4

januar: 55,54
juli i fjor: 52,83
april i fjor: 46,55

2021:

2020:

Ebitor · april 2, 2021, 3:03pm

Det mest markante i denne sammenheng er PHOs største aksjonær - Morgan Stanley LLC, som ukentlig akkumulerer.
Utskriften pr 22.03 viser nå en beholdning på 1.516.262 aksjer.
Om det skulle komme et bud på PHO, tror jeg nettopp at det kommer fra investoren bak dette finanskonsernet

Savepig · april 2, 2021, 4:32pm

En eller annen aktør med tilknytning til Boston Scientific er fremdeles min mistanke.

TekBot · april 6, 2021, 5:32am

Photocure to Present at Two Healthcare-Focused Investor Conferences in April

Press Release - Oslo, Norway, 6 April 2021, Photocure ASA (OSE: PHO), The
Bladder Cancer Company, announces that President and Chief Executive Officer,
Daniel Schneider and Chief Financial Officer, Erik Dahl are scheduled to present
…

Vis børsmeldingen

corporate overviews at two upcoming Healthcare Conferences in April.

Presentation details are as follows:
Solebury Trout European Biotech Investor Day: on April 7, 2021, Photocure
presents at 7:30pm CET / 1:30pm ET followed by individual investor meetings.
This virtual conference sponsored by Goodwin, Solebury Trout, Deutsche Bank and
NASDAQ showcases European biotech & healthcare companies.
You can sign up for the webcast
here (Loading...).

Needham Annual Healthcare Conference: on April 15, 2021, Photocure presents at
2:45pm CET / 8:45am ET followed by individual investor meetings. This 20[th]
annual conference is sponsored by the U.S. bank Needham & Company.
Access to the live event/webcast is available
here (https://wsw.com/webcast/needham107/pho.ol/2530528Photocure).

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

David Moskowitz
Head of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media Enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

Kilde

TekBot · april 9, 2021, 6:09am

Photocure ASA – Major shareholding disclosure

rosk82 · april 9, 2021, 6:15am

Capture

Savepig · april 9, 2021, 6:16am

Må vel nesten være innenfor denne posten?